Review of the contemporary cytotoxic and biologic combinations available for the treatment of metastatic breast cancer.
about
Risk of serious toxicity in 1181 patients treated in phase I clinical trials of predominantly targeted anticancer drugs: the M. D. Anderson Cancer Center experienceEnhanced apoptotic effects by the combination of curcumin and methylseleninic acid: potential role of Mcl-1 and FAK.Ixabepilone as monotherapy or in combination with capecitabine for the treatment of advanced breast cancer.Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatmentDifferential microstructure and physiology of brain and bone metastases in a rat breast cancer model by diffusion and dynamic contrast enhanced MRI.RhoB mediates antitumor synergy of combined ixabepilone and sunitinib in human ovarian serous cancer.Coadministration of lapatinib increases exposure to docetaxel but not doxorubicin in the small intestine of miceMultimodality imaging of tumor and bone response in a mouse model of bony metastasis.Synergistic enhancement of cancer therapy using a combination of ceramide and docetaxel.Platinum-based compounds for the treatment of metastatic breast cancer.Systemic treatment with capecitabine as maintenance therapy in patients with recurring or metastatic breast cancer: experience in the Oncology Hospital, National Medical Center Siglo XXI, Mexican Social Security Institute.Preclinical Remodeling of Human Prostate Cancer through the PTEN/AKT Pathway.Effect of triacontanol on the pharmacokinetics of docetaxel in rats associated with induction of cytochrome P450 3A1/2.Major changes in chemotherapy regimens administered to breast cancer patients during 2000-2008 in the Netherlands.A nation-wide multicenter 10-year (1999-2008) retrospective study of chemotherapy in Chinese breast cancer patients.Similar survival with single-agent capecitabine or taxane in first-line therapy for metastatic breast cancer.Ceramide lipid-based nanosuspension for enhanced delivery of docetaxel with synergistic antitumor efficiency.
P2860
Q33399986-C194A0BB-DCB1-4FE6-9579-D9E63086DCB7Q34639407-C77A8014-1415-4DF0-997C-ECCF6A1B63ADQ34788890-2957C254-5C4F-4595-8EAF-47B888255019Q35558126-BCE89EC3-2676-4398-9397-B42A450CA0CDQ35600833-9D4ECC1F-1582-4133-81E7-9F693DA9EE9FQ36308299-D7C155F8-3EBE-449E-B20A-D9416CA478ABQ36411053-5D8D98EB-5E9A-439D-9A8F-8C51D452A63FQ36525775-0B1A2769-6666-4230-8FFD-CCB8E5A1DCC1Q37684044-967ED156-874F-4EFF-9975-9C7B697D7AD2Q37976172-ED4BDD3B-03CC-4F5B-B359-54737852EF0AQ41346534-C360D355-68D6-4591-9CE0-6B22B4DD4DB8Q42014039-ACA98B0F-DF4B-4B89-8211-E726D27390DAQ43442709-9861170E-7E15-4731-937E-462A522DF998Q43796802-79855DAA-EE27-43AF-B3B4-33A139F6F09DQ46246572-D1C220D6-9FD5-4769-86B4-D4CD35485110Q47967056-1E83B07F-EA74-431D-BBED-247B35F80CE6Q50642939-23313975-0903-498D-ACF1-F9A445A6C162
P2860
Review of the contemporary cytotoxic and biologic combinations available for the treatment of metastatic breast cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Review of the contemporary cyt ...... t of metastatic breast cancer.
@en
Review of the contemporary cyt ...... t of metastatic breast cancer.
@nl
type
label
Review of the contemporary cyt ...... t of metastatic breast cancer.
@en
Review of the contemporary cyt ...... t of metastatic breast cancer.
@nl
prefLabel
Review of the contemporary cyt ...... t of metastatic breast cancer.
@en
Review of the contemporary cyt ...... t of metastatic breast cancer.
@nl
P1476
Review of the contemporary cyt ...... t of metastatic breast cancer.
@en
P2093
Katherine H Rak Tkaczuk
P304
P356
10.1016/J.CLINTHERA.2009.11.011
P478
P577
2009-01-01T00:00:00Z